Ignite Creation Date:
2024-05-06 @ 4:25 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04984369
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-21
First Post:
2021-07-27
Brief Title:
The Efficacy of HLX208 BRAF V600E Inhibitor With Cetuximab for Metastatic Colorectal Cancer mCRC With BRAF V600E Mutation After First-line Treatment
Sponsor:
Shanghai Henlius Biotech
Organization:
Shanghai Henlius Biotech
Study Overview
Official Title:
An Open Multicenter Phase II Clinical Study to Evaluate Safety and Efficacy of HLX208 BRAF V600E Inhibitor Combined With Cetuximab in Patients With Metastatic Colorectal Cancer mCRC
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open multicenter phase II clinical study to evaluate safety and efficacy of HLX208 BRAF V600E inhibitor combined with cetuximab for metastatic colorectal cancer mCRC with BRAF V600E Mutation after first-line treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None